Arrowhead Q3 Loss Wider Than Expected, but Pipeline and Commercial Momentum Surge
ARWR has more than doubled off its 52-week low of $15.01.
Summary
Arrowhead's Q3 loss missed expectations, but REDEMPLO sales doubled, plozasiran's pivotal data was stellar, and a Priority Review Voucher was acquired to speed its sNDA. A new Madrigal partnership adds up to $975M in milestones.
Key Events · Earnings and Guidance · ARWR
-
Q3 Loss Wider Than Expected
Net loss of $1.36 per share vs. $1.26 a year ago, missing consensus. Revenue jumped to $75.3M from $27.8M, driven by REDEMPLO.
-
REDEMPLO Prescriptions Doubled
U.S. launch momentum accelerated with prescription volume roughly doubling quarter-over-quarter. Over 400 unique prescribers now have experience with the drug.
-
Plozasiran Phase 3 Data Exceed Expectations
SHASTA-3 and SHASTA-4 met all endpoints: median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events. Full data at ESC Congress on August 30.
-
Priority Review Voucher Acquired
Arrowhead purchased an FDA PRV to use with the plozasiran sNDA submission expected by end of 2026, potentially cutting review time from 10 to 6 months.
Analysis · ARWR · Life Sciences
Arrowhead reported a fiscal Q3 loss of $1.36 per share, missing estimates, but the story is overwhelmingly about pipeline execution and commercial traction. REDEMPLO prescriptions doubled, the company acquired a Priority Review Voucher to accelerate plozasiran's sNDA, and Phase 3 SHASTA data showed unprecedented reductions in acute pancreatitis. With $1.57 billion in cash, the balance sheet supports the ambitious pipeline. The Madrigal deal for ARO-PNPLA3 adds non-dilutive capital and validates the platform. The market will likely focus on the transformative clinical data and regulatory catalysts over the near-term earnings miss.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40% of the 1112 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARWR was trading at $90.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $15.01 to $95.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.